Company intelligence / Profile preview
SirTLab
Nes-Ziona, Central, Israelsirtlabcorp.com ↗
- Ownership
- Private
- Employees
- ~49
- Development stage
- Commercial
01
Overview
SirTLab’s pipeline includes at least three named programs using different modalities to boost or restore expression of the sirtuin 6 protein. The lead program is expected to enter human trials in late 2024. All programs are currently in preclinical or IND-enabling stages.
- Therapeutic areas
- Metabolic DisordersOtherRheumatologyGastroenterologyNeurology
- Modalities
- Small moleculemRNA-based drugsAdeno-associated virus (AAV) gene therapyAntagonist for micro-RNAs (miRNA therapy)
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
03
Partnerships
No major pharma partnerships disclosed as of June 2025; collaborations with academic leaders noted.
Beyond the preview
Go deeper on SirTLab.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SirTLab.